Performance evaluation of the CHEMBIO DPP® (dual path platform) HIV-1/2 assay in early and established infections

The DPP® technology showed no significant improvement for detecting early infections over other lateral-flow RTs used in the U.S. Without more data on the DPP® HIV-1/2 assay, especially from whole blood and oral fluid specimens collected during the early phase of infection, its performance as point-of-care technology remains to be assessed.